The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Grishin G.N.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Radiology Research Center

Kukhtin A.O.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Radiology Research Center

Bespalov P.D.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Radiology Research Center

Biryukov V.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Poluektova M.V.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Radiology Research Center

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

The effectiveness of laboratory and radiological diagnosis of localized and locally advanced prostate cancer

Authors:

Grishin G.N., Kukhtin A.O., Bespalov P.D., Biryukov V.A., Poluektova M.V., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(4): 20‑27

DOI: 10.17116/onkolog20221104120

Read: 1154 times

Download PDF (RU)
Contact the author
Table of contents

THE EFFECTIVENESS OF LABORATORY AND RADIOLOGICAL DIAGNOSIS OF LOCALIZED AND LOCALLY ADVANCED PROSTATE CANCER
THE EFFECTIVENESS OF LABORATORY AND RADIOLOGICAL DIAGNOSIS OF LOCALIZED AND LOCALLY ADVANCED PROSTATE CANCER

To cite this article:

Grishin GN, Kukhtin AO, Bespalov PD, Biryukov VA, Poluektova MV, Kaprin AD. The effectiveness of laboratory and radiological diagnosis of localized and locally advanced prostate cancer. P.A. Herzen Journal of Oncology. 2022;11(4):20‑27. (In Russ.)
https://doi.org/10.17116/onkolog20221104120

Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
Resu­lts of the impact of personalized reha­bilitation on the quality of life of men after lapa­roscopic prostatectomy. P.A. Herzen Journal of Onco­logy. 2024;(4):22-28
Pote­ntial of specialized diet therapy in redu­cing toxic mani­festations in patients with meta­static castration-resistant prostate cancer with bone meta­stases during radionuclide therapy with radium chlo­ride [223Ra]. P.A. Herzen Journal of Onco­logy. 2024;(6):33-41
Remote resu­lts of treatment of patients with prostate cancer who unde­rwent radiation therapy in a combined version. P.A. Herzen Journal of Onco­logy. 2025;(3):14-19
Patterns of CAF expression in tumors of the geni­tourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35
Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medi­cine. 2025;(7):111-118

OBJECTIVE

To investigate the diagnostic value of transrectal ultrasound (TRUS), multiparametric magnetic resonance imaging (mpMRI), total prostate-specific antigen (tPSA), and prostate-specific antigen density (PSAD) in the detection of localized and locally advanced prostate cancer (PC).

Subjects and methods. To estimate the information value of methods for diagnosing PC, 44 patients aged 46 to 81 years (65.73±8.36 years) were examined retrospectively in 2019 and 2020. Patients were selected on the basis of the results of mpMRI, TRUS, and tPSA performed no more than 3 months before TRUS-guided multifocal prostate biopsy, followed by morphological and histochemical studies. Because of the insufficient information value of TRUS in determining distant processes in PC, this study will carry out a statistical analysis only for localized and locally advanced neoplasms.

RESULTS

The sensitivity, specificity, and positive predictive value, negative predictive value, and accuracy of TRUS and mpMRI were 90, 50, 34.6, 94.4, and 63.6% (p=0.024; f=0.031) and 77.8, 53.8, 53.8, 77.8, and 63.6% (p=0.036; f=0.061), respectively. There was a direct, statistically significant moderate correlation (rs=0.540) for tPSA and morphological diagnosis in the age group of 71-81 years (n=14; p=0.046). There was a direct, statistically significant moderate correlation between TRUS, mpMRI, and morphological diagnosis (rs=0.351) (n=44; p=0.019) and rs=0.373 (n=44; p=0.013), respectively. Statistically significant results could not be obtained for PSAD.

CONCLUSION

The findings allow the authors recommend using tPSA, TRUS, and mpMRI to diagnose localized and locally advanced PC.

Keywords:

prostate cancer
prostate-specific antigen
prostate-specific antigen density
multiparametric magnetic resonance imaging
transrectal ultrasound
color Doppler mapping

Authors:

Grishin G.N.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Radiology Research Center

Kukhtin A.O.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Radiology Research Center

Bespalov P.D.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Radiology Research Center

Biryukov V.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Poluektova M.V.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Radiology Research Center

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

Received:

22.02.2022

Accepted:

08.04.2022

List of references:

  1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89.  https://doi.org/10.14740/wjon1191
  2. Liang L, Zhi X, Sun Y, Li H, Wang J, Xu J, Guo J. A nomogram based on a multiparametric ultrasound radiomics model for discrimination between malignant and benign prostate lesions. Front Oncol. 2021;11:610785. https://doi.org/10.3389/fonc.2021.610785
  3. Kaprin AD, Starinskii VV, Petrova GV, eds. Zlokachestvennye novoobrazovaniya v Rossii v 2019 (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Ministerstva zdravookhraneniya Rossiiskoi Federatsii; 2021. (In Russ.).
  4. EAU Guidelines 2019: Prostate Cancer. https://uroweb.org/wp-content/uploads/EAU-EANM-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-2019-1.pdf
  5. Catalona WJ. Prostate cancer screening. Med Clin North Am. 2018;102(2): 199-214.  https://doi.org/10.1016/j.mcna.2017.11.001
  6. Kadrev AV, Mit’kova MD, Ryazantsev AA, Kamalov AA, Mit’kov VV. Quantitative contrast enhanced transrectal ultrasound (indices) in the diagnosis of prostate cancer: preliminary results. Ul’trazvukovaya i funktsional’naya diagnostika. 2020;(2):13-26. (In Russ.). https://doi.org/10.24835/1607-0771-2020-2-13-26
  7. Chigireva IB, Panchenko SV, Sharafutdinov MG, Toneeva MA. Application of non-invasive methods for prostate cancer diagnostics. Ul’yanovskii mediko-biologicheskii zhurnal. 2018;(1):80-85. (In Russ.). https://doi.org/10.23648/UMBJ.2018.29.11363
  8. Karman AV, Krasnii SA, Shimanets SV. Targeted histology sampling from atypical small acinar proliferation area detected by repeat transrectal prostate biopsy. Onkourologiya. 2017;13(1):91-100. (In Russ.). https://doi.org/10.17650/1726-9776-2017-13-1-91-100
  9. Dolotkazin DR, Shkurnikov MYu, Alekseev BYa. The role of microRNA in the diagnosis of prostate cancer. Onkourologiya. 2020;16(4):172-180. (In Russ.). https://doi.org/10.17650/1726-9776-2020-16-4-172-180
  10. Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, Bawor M, Banfield L, Profetto J. Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis. Ann Fam Med. 2018;16(2):149-154.  https://doi.org/10.1370/afm.2205
  11. Klinicheskie rekomendatsii. Rak predstatel’noi zhelezy. Odobreno na zasedanii nauchno-prakticheskogo soveta Ministerstva zdravookhraneniya Rossiiskoi Federatsii (protokol ot 25.12.20 No. 17-4/4884). 2021. (In Russ.).
  12. Streicher J, Meyerson BL, Karivedu V, Sidana A. A review of optimal prostate biopsy: indications and techniques. Ther Adv Urol. 2019;11:1756287219870074. https://doi.org/10.1177/1756287219870074
  13. Nesterov SN, Khanaliev BV, Kosarev EI, Magomedov ShS, Barsegyan AG, Bonetskii BA, Vasil’ev VR, Alymov AA. Diagnosis of prostate cancer in patients with subthreshold values of total PSA blood. Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N.I. Pirogova. 2018;13(2):91-94. (In Russ.).
  14. Kosarev EI, Nesterov SN, Khanaliev BV. The use of tumor markers in urological practice: PSA as the most frequently used marker in the differential diagnosis of an oncourologists. Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N.I. Pirogova. 2018;13(4):143-146. (In Russ.). https://doi.org/10.25881/BPNMSC.2018.52.12.028
  15. Musaelyan AA, Nazarov VD, Lapin SV, Boriskin AG, Reva SA, Lebedev DG, Yakovlev VD, Viktorov DA, Toropovskii AN, Emanuel VL, Al-Shukri SKh, Petrov SB. Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer. Onkourologiya. 2020;16(2):65-73. (In Russ.). https://doi.org/10.17650/1726-9776-2020-16-2-65-73
  16. Taratkin MS, Laukhtina EA, Adel’man KI, Alyaev YuG, Rapoport LM, Alekseeva TM, Enikeev DV, Glybochko PV. Active surveillance for prostate cancer: to whom, when and how. Sechenovskii vestnik. 2019;10(3):37-44. (In Russ.). https://doi.org/10.47093/22187332.2019.3.37-44
  17. Sfoungaristos S, Perimenis P. PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer. Can Urol Ass J. 2012;6(1):46-50.  https://doi.org/10.5489/cuaj.11079
  18. National Comprehensive Cancer Network. Prostate cancer (version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
  19. Lee SJ, Oh YT, Jung DC, Cho NH, Choi YD, Park SY. Combined analysis of biparametric MRI and prostate-specific antigen density: role in the prebiopsy diagnosis of gleason score 7 or greater prostate cancer. AJR Am J Roentgenol. 2018;211(3):166-172.  https://doi.org/10.2214/AJR.17.19253
  20. Mehralivand S, Shih JH, Rais-Bahrami S, Oto A, Bednarova S, Nix JW, Thomas JV, Gordetsky JB, Gaur S, Harmon SA, et al. A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification. JAMA Oncol. 2018;4(5):678-85.  https://doi.org/10.1001/jamaoncol.2017.5667
  21. Pushkar’ DYu, Rasner PI. Diagnostika i lechenie lokalizovannogo raka predstatel’noi zhelezy. M.: MEDpress-inform; 2008. (In Russ.).
  22. Tsarik GN, ed. Informatika i meditsinskaya statistika. M.: GEOTAR-Media; 2017. (In Russ.).
  23. Tonkoshkur AN. The role of transrectal ultrasound in the diagnosis of localized (T1-T2) prostate cancer. Byulleten’ meditsinskikh internet-konferentsii. 2015;5(5):418. (In Russ.).
  24. Nevirovich ES, Boriskin AG. New approaches to preclinical diagnosis of prostate cancer. Nephrologiya. 2017;21(5):65-70. (In Russ.). https://doi.org/10.24884/1561-6274-2017-21-5-65-70
  25. Zhavoronkov LP. Osnovy prikladnoi mediko-biologicheskoi statistiki. Meditsinskii radiologicheskii nauchnyj tsentr Ministerstva zdravookhraneniya i social’nogo razvitiya Rossiiskoi Federatsii. Obninsk: MRNTs; 2012. (In Russ.).
  26. Hectors SJ, Cherny M, Yadav KK, Beksaç AT, Thulasidass H, Lewis S, Davicioni E, Wang P, Tewari AK, Taouli B. Radiomics features measured with multiparametric magnetic resonance imaging predict prostate cancer aggressiveness. J Urol. 2019;202(3):498-505.  https://doi.org/10.1097/JU.0000000000000272
  27. Sun C, Chatterjee A, Yousuf A, Antic T, Eggener S, Karczmar GS, Oto A. Comparison of T2-Weighted Imaging, DWI, and dynamic contrast-enhanced MRI for calculation of prostate cancer index lesion volume: correlation with whole-mount pathology. AJR Am J Roentgenol. 2019;212(2):351-356.  https://doi.org/10.2214/AJR.18.20147
  28. Peshkov MN. Epigenetic markers of early diagnostics of prostate cancer. Klinicheskaya Laboratornaya Diagnostika. 2018;63(10):605-609. (In Russ.). https://doi.org/10.18821/0869-2084-2018-63-10-605-609
  29. Abdulaeva ZI, Kurbanbaeva DF, Topuzov ME. Model of the aggregate matrix calculator for the analysis of empirical data in the intelligent medical systems. Vrach i Informatsionnye Tekhnologii. 2018;(1):50-5. (In Russ.).
  30. Dolotkazin DR, Shkurnikov MYu, Alekseev BYa. The role of microRNA in the diagnosis of prostate cancer. Onkourologiya. 2020;16(4):172-180. (In Russ.). https://doi.org/10.17650/1726-9776-2020-16-4-172-180
  31. Nan LB, Yin XT, Gao JP. Significant diagnostic value of free-serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for prostate cancer of the Chinese population in a single institution. Med Sci Monit. 2019;25:8345-8351. https://doi.org/10.12659/MSM.916900
  32. Saema A, Kochakarn W, Lertsithichai P. PSA density and prostate cancer detection. J Med Assoc Thai. 2012;95(5):661-666. 
  33. Nasrullayev MM, Nasrullayev MN, Nasrullayev MM. Complex echography in the diagnosis and monitoring the effectiveness of treatment for prostate cancer. Povolzhskii Onkologicheskii Vestnik. 2018;10(4):37-41. (In Russ.).
  34. Savushkin MS, Belova IB. The transrectal dopplerography in diagnostics of diseases of a prostate. Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N.I. Pirogova. 2013;8(2):83-86. (In Russ.).
  35. Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045-1053. https://doi.org/10.1016/j.eururo.2015.01.013
  36. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822.  https://doi.org/10.1016/S0140-6736(16)32401-1

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.